Erenumab Remains Safe, Tolerable Over 3-Plus Years of Treatment in Episodic Migraine
In their interim analysis of a 5-year open-label extension trial, study investigators evaluated the safety and tolerability of erenumab treatment in episodic migraine patients who completed ≥3 years of the trial or discontinued treatment.